Treatment options for psoriatic arthritis (PsA) increased significantly in the last decade with leflunomide and tumor necrosis factor (TNF) inhibitors (TNFi) becoming part of our standard therapeutic arsenal [1]. The gene discussed is TNF; the disease is psoriatic arthritis.